CSF and clinical hallmarks of subcortical dementias: Focus on DLB and PDD

Journal of Neural Transmission

Volumn 119, Issue 7, 2012, Pages 861-875

  Stefani, Alessandro ^a,b   Brusa, Livia ^c   Olivola, Enrica ^a   Pierantozzi, Mariangela ^a,b   Martorana, Alessandro ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c S EUGENIO HOSPITAL   (Italy)

Author keywords

CSF biomarkers; Dementia; Lewi body disorders; Parkinson's disease

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; LEVODOPA; PRAMIPEXOLE; TAU PROTEIN;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; EXECUTIVE FUNCTION; EXTRAPYRAMIDAL SYNDROME; FOLLOW UP; HUMAN; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROPSYCHOLOGICAL TEST; NONHUMAN; PARKINSON DISEASE; PARKINSON DISEASE WITH DEMENTIA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; BRAIN; DEMENTIA; HUMANS; LEWY BODY DISEASE; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE;

EID: 84863499312     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-012-0820-0     Document Type: Review

References (96)

1. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sørensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60:387-392
2. Aarsland D, Kurz M, Beyer M, Bronnik K, Piepenstock Nore S, Ballard C (2008) Early discriminatory diagnosis of dementia with Lewy bodies. Dem Other Cogn Dis. 17:195-205
3. Aasly JO, Shi M, Sossi V, Stewart T, Johansen KK, Wszolek ZK, Uitti RJ, Hasegawa K, Yokoyama T, Zabetian CP, Kim HM, Leverenz JB, Ginghina C, Armaly J, Edwards KL, Snapinn KW, Stoessl AJ, Zhang J (2012) Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers. Neurology 78:55-61
4. Alves G, Brønnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, Kurz MW, Andreasson U, Tysnes OB, Larsen JP, Mulugeta E (2010) CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 81:1080-1086
5. Andersson M, Zetterberg H, Minthon L, Blennow K, Londos E (2011) The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia. Int J Geriatr Psychiatry 26:100-105
6. Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki HW, Sparbier K, Smirnov A, Cepek L, Trenkwalder C, Rüther E, Kornhuber J, Otto M, Wiltfang J (2006) CSF amyloid-betapeptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 129:1177-1187
7. Biju G, de la Fuente-Fernández R (2009) Dopaminergic function and progression of Parkinson's disease: PET findings. Parkinsonism Relat Disord Suppl 4:S38-S40
8. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E (1995) Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26:231-245
9. Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT, Irizarry MC, Wahlund LO, Lannfelt L, Ingelsson M (2009) Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Dement Geriatr Cogn Disord 27:458-464
10. Brooks DJ (2009) Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography. Mov Disord 2(24 Suppl):S742-S747
11. Brusa L, Bassi A, Stefani A, Pierantozzi M, Peppe A, Caramia MD et al (2003) Pramipexole in comparison to l-dopa: a neuropsychological study. J Neural Transm 110:373-380
12. Brusa L, Tiraboschi P, Koch G, Peppe A, Pierantozzi M, Ruggieri S et al (2005) Pergolide effect on cognitive functions in early-mild Parkinson's disease. J Neural Transm 112:231-242
13. Carmichael O, Schwarz C, Drucker D, Fletcher E, Harvey D, Beckett L, Jack CR Jr, Weiner M, DeCarli C, Alzheimer's Disease Neuroimaging Initiative (2010) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch Neurol 67:1370-1378
14. Compta Y, MartíMJ, Ibarretxe-Bilbao N, JunquéC, Valldeoriola F, Muñoz E, Ezquerra M, Ríos J, Tolosa E (2009) Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov Disord 24:2203-2210
15. Compta Y, Parkkinen L, O'Sullivan SS, Vandrovcova J, Holton JL, Collins C, Lashley T, Kallis C, Williams DR, de Silva R, Lees AJ, Revesz T (2011) Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 134:1493-1505
16. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P (2010) Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 9:1118-1127
17. Formichi P, Parnetti L, Radi E, Cevenini G, Dotti MT, Federico A (2008) CSF levels of beta-amyloid 1-42, tau and phosphorylated tau protein in CADASIL. Eur J Neurol 15(11):1252-1255
18. Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, Holtzman DM (2005) Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci 25:2803-2810
19. Galpern WR, Lang AE (2006) Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 59:449-458
20. Girotti F, Soliveri P, Carella F, Piccolo I, Caffarra P, Musicco M, Saraceni T (1988) Dementia and cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry 51:1498-1502
21. Gomez-Tortosa E, Gonzalo I, Fanjul S, Sainz MJ, Cantarero S, Cemillàn C (2003) Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease. Arch Neurol 60:1218-1222
22. Gomis M, Sobrino T, Ois A, Millán M, Rodríguez-Campello A, Pérez de la Ossa N, Rodríguez-González R, Jiménez-Conde J, Cuadrado-Godia E, Roquer J, Dávalos A (2009) Plasma betaamyloid 1-40 is associated with the diffuse small vessel disease subtype. Stroke 40(10):3197-3201
23. Goos JD, Teunissen CE, Veerhuis R, Verwey NA, Barkhof F, Blankenstein MA, Scheltens P, van der Flier WM (2012) Microbleeds relate to altered amyloid-beta metabolism in Alzheimer's disease. Neurobiol Aging 33:1011.e1-e9
24. Grilli M, Lagomarsino F, Zappettini S, Preda S, Mura E, Govoni S, Marchi M (2010) Specific inhibitory effect of amyloid-beta on presynaptic muscarinic receptor subtypes modulating neurotransmitter release in the rat nucleus accumbens. Neuroscience 167(2):482-489
25. Haldenwanger A, Eling P, Kastrup A, Hildebrandt H (2010) Correlation between cognitive impairment and CSF biomarkers in amnesic MCI, non-amnesic MCI, and Alzheimer's disease. J Alzheimers Dis 22:971-980
26. Halliday GM, Song YJ, Harding AJ (2011) Striatal β-amyloid in dementia with Lewy bodies but not Parkinson's disease. J Neural Transm 118:713-719
27. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5(3):228-234
28. Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK (2011) Alzheimer's disease neuroimaging initiative. Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology 77:1619-1628
29. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 23:837-844
30. Himeno E, Ohyagi Y, Ma L, Nakamura N, Miyoshi K, Sakae N, Motomura K, Soejima N, Yamasaki R, Hashimoto T, Tabira T, LaFerla FM, Kira J (2011) Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation. Ann Neuro 69:248-256
31. Holmberg B, Johnels B, Blennow K, Rosengren L (2003) Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov Disord 18:186-190
32. Jellinger KA (2009) Significance of brain lesions in Parkinson disease dementia and Lewy body dementia. Front Neurol Neurosci 24:114-125
33. Kahle PJ, Jakowec M, Teipel SJ, Hampel H, Petzinger GM, Di Monte DA, Silverberg GD, Möller HJ, Yesavage JA, Tinklenberg JR, Shooter EM, Murphy GM Jr (2000) Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF. Neurology 54:1498-1504
34. Kalaitzakis ME, Walls AJ, Pearce RK, Gentleman SM (2011) Striatal Aβ peptide deposition mirrors dementia and differentiates DLB and from other parkinsonian syndromes. Neurobiol Dis 41:377-384
35. Kanemaru K, Kameda N, Yamanouchi H (2000) Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies. Neurology 54:1875-1876
36. Kantarci K, Lowe VJ, Boeve BF, Weigand SD, Senjem ML, Przybelski SA, Dickson DW, Parisi JE, Knopman DS, Smith GE, Ferman TJ, Petersen RC, Jack CR Jr (2011) Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging 2011 Oct 20
37. Kar S, Slowikowski SP, Westaway D, Mount HT (2004) Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease. J Psychiatry Neurosci 29:427-441
38. Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O, Nishizawa M, Ikeuchi T (2010) Differential levels of alphasynuclein, beta-amyloid 42 and tau in CSF patients with dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychiatry 81:608-610
39. Kester MI, Boelaarts L, Bouwman FH, Vogels RL, Groot ER, van Elk EJ, Blankenstein MA, van der Flier WM, Scheltens P (2010) Diagnostic impact of CSF biomarkers in a local hospital memory clinic. Dement Geriatr Cogn Disord 29:491-497
40. Kumar U, Patel SC (2007) Immunohistochemical localization of DA receptor subtypes (D1R-D5R) in Alzheimer's disease brain. Brain Res 1131:187-196
41. Kurz A, Riemenschneider M, Wallin A (2003) Potential biological markers for cerebrovascular disease. Int Psychogeriatr 15(Suppl 1):89-97
42. Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, Shaw LM, Trojanowski JQ, Jack CR Jr, Weiner MW, Jagust WJ, Alzheimer's Neuroimaging Initiative (2010) Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 75:230-238
43. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW, PBT2-201-EURO Study Group (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7:779-786
44. Leverenz JB, Watson GS, Shofer J, Zabetian CP, Zhang J, Montine TJ (2011) Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease. Parkinsonism Relat Disord 17:61-64
45. Lewczuk P, Popp J, Lelental N, Kölsch H, Maier W, Kornhuber J, Jessen F (2012) Cerebrospinal fluid soluble amyloid-β protein precursor as a potential novel biomarkers of Alzheimer's disease. J Alzheimers Dis 28:119-125
46. LeWitt PA, Galloway MP, Matson W, Milbury P, McDermott M, Srivastava DK, Oakes D (1992) Markers of DA metabolism in Parkinson's disease. The Parkinson Study Group. Neurology 42:2111-2117
47. Lunardi G, Galati S, Tropepi D, Moschella V, Brusa L, Pierantozzi M, Stefani A, Rossi S, Fornai F, Fedele E, Stanzione P, Hainsworth AH, Pisani A (2009) Correlation between changes in CSF DA turnover and development of dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 15:383-389
48. Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, Becker C, Schulte C, Leyhe T, Keller S, Melms A, Gasser T, Berg D (2009) Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 34:107-112
49. Martorana A, Stefani A, Palmieri MG, Esposito Z, Bernardi G, Sancesario G, Pierantozzi M (2008) L-Dopa modulates motor cortex excitability in Alzheimer's disease patients. J Neural Transm 115:1313-1319
50. Martorana A, Mori F, Esposito Z, Kusayanagi H, Monteleone F, CodecàC, Sancesario G, Bernardi G, Koch G (2009) DA modulates cholinergic cortical excitability in Alzheimer's disease patients. Neuropsychopharmacology 34:2323-2328
51. Martorana A, Esposito Z, Koch G (2010) Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease? CNS Neurosci Ther 16:235-245
52. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, PirttiläT, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease inpatients with mild cognitive impairment. JAMA 302:385-393
53. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, Forlenza O, Frisoni GB, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovits AZ, Herukka SK, Holtzman DM, Humpel C, Hyman BT, Iqbal K, Jucker M, Kaeser SA, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen CS, Kummer MP, Lui J, LladóA, Lewczuk P, Li QX, Martins R, Masters C, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine TJ, Nowatzke W, O'Brien R, Otto M, Paraskevas GP, Parnetti L, Petersen RC, Prvulovic D, de Reus HP, Rissman RA, Scarpini E, Stefani A, Soininen H, Schröder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tumani H, Umek RM, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek MM, Windisch M, Zhang J, Zetterberg H, Blennow K (2011) The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 7:386-395
54. McKeith I (2007) Dementia with Lewy bodies and Parkinson's disease with dementia: where two worlds collide. Pract Neurol 7:374-382
55. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M, Consortium on DLB (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863-1872
56. Metzler-Baddeley C (2007) A review of cognitive impairments in dementia with Lewy bodies relative to Alzheimer's disease and Parkinson's disease with dementia. Cortex 43:583-600
57. Mollenhauer B, Cepek L, Bibl M, Wiltfang J, Schulz-Schaeffer WJ, Ciesielczyk B (2005) Tau protein, A β42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord 19:164-170
58. Mollenhauer B, Trenkwalder C, von Ahsen N, Bibl M, Steinacker P, Brechlin P, Schindehuette J, Poser S, Wiltfang J, Otto M (2006) Beta-amyloid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord 22:200-208
59. Mollenhauer B, Esselmann H, Trenkwalder C, Schulz-Schaeffer W, Kretzschmar H, Otto M, Wiltfang J, Bibl M (2011) CSF amyloid-β peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer's disease. J Alzheimers Dis 24:383-391
60. Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, Chung KA, Kim H, Galasko DR, Jankovic J, Zabetian CP, Leverenz JB, Zhang J (2010) CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord 25:2682-2685
61. Mulugeta E, Londos E, Ballard C, Alves G, Zetterberg H, Blennow K, Skogseth R, Minthon L, Aarsland D (2011a) CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 82:160-164
62. Mulugeta E, Londos E, Hansson O, Ballard C, Skogseth R, Minthon L, Blennow K, Zetterberg H, Aarsland D (2011b) Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's disease: clinical and neurochemical correlates. Int J Alzheimers Dis 2011:495025
63. Mura E, Preda S, Govoni S, Lanni C, Trabace L, Grilli M, Lagomarsino F, Pittaluga A, Marchi M (2010) Specific neuromodulatory actions of amyloid-beta on DA release in rat nucleus accumbens and caudate putamen. J Alzheimers Dis 19:1041-1053
64. Ohrfelt A, Grognet P, Andreasen N, Wallin A, Vanmechelen E, Blennow K, Zetterberg H (2009) Cerebrospinal fluid alphasynuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett 450:332-335
65. PappatàS, Santangelo G, Aarsland D, Vicidomini C, Longo K, Bronnick K, Amboni M, Erro R, Vitale C, Caprio MG, Pellecchia MT, Brunetti A, De Michele G, Salvatore M, Barone P (2011) Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism. Neurology 77:1357-1362
66. Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D'Amore C, Pierguidi L, Tambasco N, Rossi A, Calabresi P (2008) Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry 64:850-855
67. Parnetti L, Chiasserini D, Eusebi P, Giannandrea D, Bellomo G, De Carlo C, Padiglioni C, Mastrocola S, Lisetti V, Calabresi P (2012) Performance of Aβ1-40, Aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. J Alzheimers Dis 29:229-238
68. Pillon B, Deweer B, Agid Y, Dubois B (1993) Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases. Arch Neurol 50:374-379
69. PřikrylováVranováH, Mareš J, Nevrlý M, Stejskal D, ZapletalováJ, Hluštík P, Kanǒ vský P (2010) CSF markers of neurodegeneration in Parkinson's disease. J Neural Transm 117:1177-1181
70. Quigley H, Colloby SJ, O'Brien JT (2011) PET imaging of brain amyloid in dementia: a review. Int J Geriatr Psychiatry 26:991-999
71. Reesink FE, Lemstra AW, van Dijk KD, Berendse HW, van de Berg WD, Klein M, Blankenstein MA, Scheltens P, Verbeek MM, van der Flier WM (2010) CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease. J Alzheimers Dis 22(1):87-95
72. Reid WG, Hely MA, Morris JG, Loy C, Halliday GM (2011) Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study). J Neurol Neurosurg Psychiatry 82:1033-1037
73. Schneider JA, Aggarwal NT, Barnes L, Boyle P, Bennett DA (2009) The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis 18:691-701
74. Schneider LS, Kennedy RE, Cutter GR, Alzheimer's Disease Neuroimaging Initiative (2010) Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement 6:367-377
75. Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, Pijnenburg YA, Blankenstein MA, Rozemuller AJ, Scheltens P, van der Flier WM (2012) Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 78:47-54
76. Selnes P, Blennow K, Zetterberg H, Grambaite R, Rosengren L, Johnsen L, Stenset V, Fladby T (2010) Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid. Cerebrospinal Fluid Res 7:10
77. SeppäläTT, Koivisto AM, Hartikainen P, Helisalmi S, Soininen H, Herukka SK (2011) Longitudinal changes of CSF biomarkers in Alzheimer's disease. J Alzheimers Dis 25:583-594
78. Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Kang UJ, Cain KC, Wang Y, Aasly J, Goldstein D, Zhang J (2011) Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 69:570-580
79. Siderowf A, Xie SX, Hurtig H, Weintraub D, Duda J, Chen-Plotkin A, Shaw LM, Van Deerlin V, Trojanowski JQ, Clark C (2010) CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease. Neurology 75:1055-1061
80. Sjögren M, Minthon L, Davidsson P, Granérus A-K, Clarberg A, Vanderstichele H, Vanmechelen E, Wallin A, Blennow K (2000) CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging.J Neural Transm 107:563-579
81. Spies PE, Slats D, Sjögren JM, Kremer BP, Verhey FR, Rikkert MG, Verbeek MM (2010) The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia. Curr Alzheimer Res 7(5):470-476
82. Stefani A, Bernardini S, Panella M, Pierantozzi M, Nuccetelli M, Koch G, Urbani A, Giordano A, Martorana A, Orlacchio A, Federici G, Bernardi G (2005) AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis. J Neurol Sci 237:83-88
83. Stefani A, Martorana A, Bernardini S, Panella M, Mercati F, Orlacchio A, Pierantozzi M (2006) CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. J Neurol Sci 251:124-128
84. Thal DR, Griffin WS, Braak H (2008) Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. J Cell Mol Med 12:1848-1862
85. Tiraboschi P, Salmon DP, Hansen LA, Hofstetter RC, Thal LJ, Corey-Bloom J (2006) What best differentiates Lewy body from Alzheimer's disease in early-stage dementia? Brain 129:729-735
86. Tschampa HJ, Schulz-Schaeffer W, Wiltfang J, Poser S, Otto M, Neumann M (2001) Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology 56:576
87. Tsuboi Y, Uchikado H, Dickson DW (2007) Neuropathology of Parkinson's disease dementia and dementia with Lewy bodies with reference to striatal pathology. Parkinsonism Relat Disord 13:221-224
88. van der Vlies AE, Verwey NA, Bouwman FH, Blankenstein MA, Klein M, Scheltens P, van der Flier WM (2009) CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. Neurology 72:1056-1061
89. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr, Alzheimer's Disease Neuroimaging Initiative (2009) MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 73:287-293
90. Verbeek MM, De Jong D, Kremer HP (2003) Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases. Ann Clin Biochem 40:25-40
91. Viswanathan A, Greenberg SM (2011) Cerebral amyloid angiopathy in the elderly. Ann Neurol 70:871-880
92. Wagner M, Wolf S, Reischies FM, Daerr M, Wolfsgruber S, Jessen F, Popp J, Maier W, Hüll M, Frölich L, Hampel H, Perneczky R, Peters O, Jahn H, Luckhaus C, Gertz HJ, Schröder J, Pantel J, Lewczuk P, Kornhuber J, Wiltfang J (2012) Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. Neurology 78:379-386
93. Weisman D, McKeith I (2007) Dementia with Lewy bodies. Semin Neurol 27:42-47
94. Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA (2007) Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 130:1787-1798
95. Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, Brayne C, Kolachana BS, Weinberger DR, Sawcer SJ, Barker RA (2009) The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 132:2958-2969
96. Wu J, Khan GM, Nichols RA (2007) DA release in prefrontal cortex in response to beta-amyloid activation of alpha7 nicotinic receptors. Brain Res 1182:82-89